US2016303206A1PendingUtilityA1

Pharmaceutical or nutritional compositions containing galactosidase, and their use

45
Assignee: ALFA WASSERMANN SPAPriority: Jul 15, 2013Filed: Jun 27, 2016Published: Oct 20, 2016
Est. expiryJul 15, 2033(~7 yrs left)· nominal 20-yr term from priority
Inventors:Alessandro ZanarottiGabriele BrunettiSergio Cecchetti
A61K 9/2013A61K 9/0053A61K 9/2009A61K 9/0056A61K 9/2018A61K 9/2054C12Y 302/01022C12Y 302/01023A61K 38/47
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present disclosure relates to pharmaceutical or nutritional compositions containing α-galactosidase and β-galactosidase and their use in the prevention and/or treatment of gastroesophageal reflux disease; in particular the present disclosure related to pharmaceutical or nutritional compositions.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical or nutritional composition containing α-galactosidase and β-galactosidase and at least one pharmaceutically acceptable excipient or carrier. 
     
     
         2 . The pharmaceutical or nutritional composition according to  claim 1 , wherein the content of α-galactosidase ranges from 75 to 2400 GalU and the content of β-galactosidase ranges from 2500 to 12500 LactU in the form of a dosage unit. 
     
     
         3 . The pharmaceutical or nutritional composition according to  claim 1 , wherein the composition is formulated for oral administration. 
     
     
         4 . The pharmaceutical or nutritional composition according to  claim 3 , wherein the composition is formulated in a solid form selected from powders, granules, tablets, pills and capsules. 
     
     
         5 . The pharmaceutical or nutritional composition according to  claim 3 , wherein the composition is formulated in a liquid form selected from emulsions, syrups, elixirs, suspensions and solutions. 
     
     
         6 . The pharmaceutical or nutritional composition according to  claim 1 , wherein the content of α-galactosidase ranges from 300 to 1200 GalU and the content of β-galactosidase ranges from 3500 to 11000 LactU in the form of a dosage unit. 
     
     
         7 . The pharmaceutical or nutritional composition according to  claim 1 , wherein the amount of α-galactosidase is 30 mg and the amount of β-galactosidase is 69 mg. 
     
     
         8 . The pharmaceutical or nutritional composition according to  claim 1 , wherein the content of α-galactosidase is 10000 GalU/g and the content of β-galactosidase is 65000 LactU/g.

Join the waitlist — get patent alerts

Track US2016303206A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.